BioMarin Pharmaceutical | BMRN - Trade Creditors


BioMarin Pharmaceutical reported $793.15M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 12.25M 1.34M Mar/2026
Agios Pharmaceuticals USD 13.75M 4.61M Mar/2026
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
Amgen USD 19.52B 1.37B Mar/2026
Bayer EUR 6.59B 496M Mar/2026
Biogen USD 358.5M 73.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Gilead Sciences USD 645M 70M Mar/2026
Incyte USD 228.62M 1.41B Mar/2026
Insmed USD 73.38M 6.53M Mar/2026
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
Moderna USD 161M 156M Mar/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
PTC Therapeutics USD 25.48M 20M Mar/2026
Puma Biotechnology USD 6.39M 962K Sep/2025
Regeneron Pharmaceuticals USD 1.03B 4.81B Mar/2026
Roche Holding CHF 5.78B 1.27B Dec/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sanofi EUR 22.71B 219M Mar/2026
Sarepta Therapeutics USD 70.38M 210.46M Mar/2026
Ultragenyx Pharmaceutical USD 42M 11M Mar/2026
United Therapeutics USD 498.3M 491.2M Mar/2026
Vertex Pharmaceuticals USD 3.47B 40.6M Mar/2026